Eris Lifesciences gains after Q1 PAT climbs 21% YoY to rs 142 cr
Mumbai, July 29 -- Revenue from operations grew 12.97% YoY to Rs 873.25 crore during the quarter.
Profit before tax (PBT) jumped 11.42% YoY to Rs 179.49 crore in Q1 FY27.
EBITDA rose 7.1% YoY to Rs 296 crore from Rs 277 crore in the year-ago quarter. However, EBITDA margin contracted to 33.9% in Q1 FY27 from 35.8% in Q1 FY26.
During the quarter, revenue from domestic branded formulations (DBF) segment stood at Rs 801 crore, up 14% YoY Meanwhile, revenue from the international business increased 5% YoY to Rs 72 crore during the quarter.
Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical produc...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.